Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
about
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisPsoriasis registries worldwide: systematic overview on registry publications.Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor AntagonistsRecapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab.Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary.Adalimumab: A Review in Chronic Plaque Psoriasis.Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist.Risk of Cancer in Patients with Psoriasis on Biologic Therapies: A Systematic Review.Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study.Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States.Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.The role of IL 23 in the treatment of psoriasis.Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE.The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.Tildrakizumab for treating psoriasis.Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort.Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.The global state of psoriasis disease epidemiology: a workshop report.Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis.Drug survival of biologic treatments in psoriasis: a systematic review.Adherence to biologics in patients with psoriasis.Differential Drug Survival of Second-Line Biologic Therapies In Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices.Drug survival rates and reasons for drug discontinuation in psoriasis.Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).Old and New Biological Therapies for Psoriasis.Patient-relevant treatment goals in psoriasis.Apremilast in psoriasis - a prospective real-world study.Biologics for psoriasis: more drugs, new patient categories, but fresh challenges for clinical dermatologists.Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.Switching of biologics in psoriasis: Reasons and results.
P2860
Q26771682-A69C4223-67E8-4B33-9AD5-2DFCCF9DEF51Q30251454-45D3B706-6178-40A8-9A7B-072E0553B764Q33646955-91CAC557-885D-42E3-A603-9DA46CB3E7D1Q36988833-BA3E5B73-BBCB-4CBC-9343-89C60D74E820Q37171259-547BA4DB-ADDF-4BCA-BD5A-F4DC32729387Q37352347-21EE68A2-EEC5-47CF-853D-28B387F07939Q37620900-7C56B768-74E3-42D5-B21C-8A95CF091861Q37712237-34743135-863E-4CBE-A1CB-E8BE2EB9842FQ38633601-86094C2F-513B-485C-AD05-8B604E2C49FDQ38639495-2F009ED1-7480-4B64-B2BB-05B9E0F94AFAQ38645111-7140AF8A-2444-4B8D-AF39-E3785191B379Q38658837-ECF307CE-708B-4AA4-8BA6-88F7DA181E2EQ38672588-50781C87-CF4F-48A1-B483-B8110E309ED0Q38733759-538E1D88-C412-44C2-A833-211FF32694C3Q38753877-949B4363-DA57-4889-8E7C-A78FD85877C8Q38902108-C6746BC2-CEED-43C7-B0CC-86913780973EQ38920742-9C3AB466-0555-408B-95D0-B0089300CE54Q38940190-1E35C1B5-92F7-4565-8FFB-7CC9C8CCC648Q38976762-688297A8-524C-41F8-BFD1-AFF95117A385Q39025609-CC1B2667-6F17-41CE-A6E9-68F80806A55AQ39064616-DA5A2A57-40F4-49ED-921A-3E4EA41761D8Q39167757-588D87E0-7734-4E3F-BC4C-AA14536716BAQ39436442-1B86A6C6-4FC2-40FC-B6EF-F328BA7E3B24Q39563205-E1AFEDAA-FD0A-460E-B67E-8BDC1F851156Q40045451-EAEFA475-487C-4B2D-9908-3AA5EF5C60E2Q40181403-63144BE2-86D6-47E7-8DB4-BFF630336E71Q40261663-37EAACC4-663E-4A42-B7C0-B310724B8319Q46118586-221CC5EC-AD68-4B01-BD12-20E89A102318Q47560483-4EDD7DBA-0D7B-48D5-97D8-06C5BF3D9CAEQ47595988-38863991-5FBE-4029-8EBF-64D9CECB92BAQ47602890-02A8DA7B-E4A7-461B-8FC1-8E5F871A4D36Q47624590-26035105-25B8-4804-816F-A27B14A2558FQ47671991-961A45A1-BA66-49A8-8F19-160CFBFD707AQ47751500-B5DC5665-4E48-4F38-A10E-959D5DED03B9Q47859049-17DEB0CB-6386-4A79-A43B-56B4BB702B33Q47877368-344A06B6-348D-4B7A-B672-D6F72840F44DQ47962744-C5EAA33B-1EEB-4C53-BE92-302C07C73470Q48088523-78D3595F-BF18-40CA-8188-1C0B60214642Q48160760-A3546643-93A6-4C3A-87B9-E453FE19DE74Q48166630-23D90AF6-48D3-4DAD-BF9D-D40CCE9907C3
P2860
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Differential Drug Survival of ...... terventions Register (BADBIR).
@en
type
label
Differential Drug Survival of ...... terventions Register (BADBIR).
@en
prefLabel
Differential Drug Survival of ...... terventions Register (BADBIR).
@en
P2093
P50
P356
P1476
Differential Drug Survival of ...... nterventions Register (BADBIR)
@en
P2093
A David Burden
Anthony D Ormerod
Caroline M Owen
Kathleen McElhone
Richard B Warren
P2888
P304
P356
10.1038/JID.2015.208
P407
P50
P577
2015-06-08T00:00:00Z